BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW

bioAffinity Technologies, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$3.51−0.22 (-5.90%)

Close on Oct 19, 2026

Market cap: $18.35M
P/E (TTM): –
Dividend yield: –

SEC filings

40 of bioAffinity Technologies's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Oct 15, 2026	Oct 15, 2026	SEC EDGAR
Current report	8-K	Oct 13, 2026	Oct 13, 2026	SEC EDGAR
Current report	8-K	Oct 8, 2026	Oct 9, 2026	SEC EDGAR
Current report	8-K	Oct 8, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Oct 6, 2026	Oct 6, 2026	SEC EDGAR
Current report	8-K	Sep 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	8-K	Sep 22, 2026	Sep 22, 2026	SEC EDGAR
Current report	8-K	Sep 17, 2026	Sep 17, 2026	SEC EDGAR
Current report	8-K	Sep 11, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 9, 2026	SEC EDGAR
Current report	8-K	Sep 3, 2026	Sep 3, 2026	SEC EDGAR
Current report	8-K	Sep 1, 2026	Sep 1, 2026	SEC EDGAR
Current report	8-K	Aug 20, 2026	Aug 20, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Aug 18, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 14, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Aug 7, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Jul 30, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	8-K	Jul 7, 2026	Jul 7, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 18, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 16, 2026	SEC EDGAR
Current report	8-K	Jun 2, 2026	Jun 2, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 11, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 14, 2026	Apr 14, 2026	SEC EDGAR
Current report	8-K	Apr 7, 2026	Apr 7, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 1, 2026	SEC EDGAR
Current report	8-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Current report	8-K	Mar 25, 2026	Mar 25, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Proxy statement	DEF 14A	Mar 16, 2026	Mar 16, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 13, 2026	Mar 13, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in bioAffinity Technologies's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Aug 24, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BIAF.

Revenue growth-23.2% · median 15.4%

Operating margin-209.8% · median -130.2%

Net margin-257.3% · median -114.9%

Company	Revenue	Growth
OABI	$38.46M	+67.0%
MXCT	$31.05M	-13.2%
FOXO	$17.86M	+44.0%
BIAF	$5.90M	-23.2%
ABSI	$1.56M	-62.3%
AIDX	–	–

Company

Next earnings (est.): Nov 13, 2026, before open
Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 57
Auditor: WithumSmith+Brown, PC
SEC CIK: 1712762

Advertisement
300 × 250